FOS and cardiac hypertrophy: Appropriately inhibiting the expression of AP-1 can effectively alleviate the cardiovascular toxicity caused by various factors, such as intimal hyperplasia, myocardial hypertrophy, hypertension, and myocardial fibrosis [37–39].